Weekly vs. Daily GLP-1s: Adherence, Results, and Who Each Suits
For most people, weekly GLP-1s have the edge. They mean fewer doses to remember, more forgiving rules for missed doses, and the strongest weight-loss results in trials so far. Daily options make sense if you already have a daily pill routine, want a medicine that leaves your body within days instead of weeks, or want to avoid needles with a once-a-day pill. The schedule matters less than finding a drug you will actually keep taking.
Key takeaways
- As of October 2026, weekly options for weight management are Wegovy injection and Zepbound. Daily options are Saxenda injection, the Wegovy pill and Foundayo.
- In the head-to-head STEP 8 trial, weekly semaglutide produced 15.8% weight loss versus 6.4% for daily liraglutide. Fewer people stopped for side effects (3.2% vs. 12.6%).
- Real-world data favor weekly drugs on persistence, but not uniformly. In one Italian study, one weekly drug had lower 6-month persistence than a daily one.
- Half-life drives what happens after a missed dose: about a week for semaglutide, 5 to 6 days for tirzepatide, 29 to 49 hours for Foundayo and about 13 hours for liraglutide.
- The newer daily pills close much of the efficacy gap with older daily drugs, but each comes with its own routine.
The options, by schedule
| Drug | Schedule and form | Half-life | Missed-dose rule (label) | Trial weight loss | Self-pay price listed |
|---|---|---|---|---|---|
| Zepbound (tirzepatide) | Weekly injection | ~5–6 days | Take within 4 days (96 hours) of the missed dose | 20.9% at 15 mg, 72 weeks (SURMOUNT-1) | $299–$449/mo by dose (KwikPen or vials) |
| Wegovy (semaglutide) injection | Weekly injection | ~1 week | Take if next dose is more than 2 days away; otherwise skip | 15.8% at 2.4 mg, 68 weeks (STEP 8) | $349/mo ($199 first 2 fills for new patients) |
| Wegovy pill (oral semaglutide) | Daily tablet, fasting | ~1 week | Skip the missed dose; take the next dose the following day | 13.6% at 25 mg, 64 weeks (OASIS 4) | $149–$299/mo, by dose |
| Foundayo (orforglipron) | Daily tablet, with or without food | ~29–49 hours | Take as soon as possible; don't double. Re-titrate after 7+ missed doses | 11.1% at 17.2 mg, 72 weeks (ATTAIN-1) | From $149/mo (lowest dose) |
| Saxenda (liraglutide) | Daily injection | ~13 hours | Resume next scheduled dose. If more than 3 days missed, restart at 0.6 mg | 6.4% at 3.0 mg, 68 weeks (STEP 8) | Check current pricing |
Source: Zepbound label (08/2026); Wegovy label (May 2026); Wegovy label incl. tablets (06/2026); Foundayo label (07/2026); Saxenda label (02/2026); trial figures and prices from sources cited in the text. Prices as listed by manufacturers in October 2026. Trials differ in design, so compare figures with caution.
Results: weekly drugs lead, but the gap is mostly about the molecule
The only large head-to-head trial of a weekly versus a daily GLP-1 for weight loss is STEP 8. Adults without diabetes lost 15.8% of body weight on weekly semaglutide 2.4 mg versus 6.4% on daily liraglutide 3.0 mg over 68 weeks. Discontinuation due to adverse events was 3.2% with semaglutide and 12.6% with liraglutide, though GI side effects were reported at similar rates (84.1% vs. 82.7%) (Patient Care, STEP 8 report).
That gap is not proof that weekly dosing itself causes more weight loss. Semaglutide and liraglutide are different molecules, and the trial was not designed to separate drug potency from schedule. The newer daily pills show this clearly. The Wegovy pill (oral semaglutide 25 mg) produced 13.6% average weight loss versus 2.4% on placebo at 64 weeks in OASIS 4. Among people who stayed on treatment, the figure was 16.6% (Novo Nordisk announcement via MarketScreener, Jan. 2026). Daily Foundayo produced 11.1% average weight loss on its top 17.2 mg dose versus 2.1% on placebo at 72 weeks, counting everyone who started, per its label. Lilly's headline figure of 12.4% assumes everyone stayed on treatment (Lilly, April 2026).
At the top end, weekly tirzepatide 15 mg produced 20.9% at 72 weeks in SURMOUNT-1 (HCPLive). No daily option has matched that in trials published so far.
Comparing weekly and daily options?
See which approved GLP-1s licensed providers offer and what they currently charge.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Adherence: what real-world data shows
The usual argument for weekly dosing is that 52 doses a year are easier to manage than 365. Real-world data generally support this, with important exceptions.
An Italian prescription database study of more than 7,000 people with type 2 diabetes looked at persistence six months after starting a GLP-1. Rates were 62% for weekly dulaglutide and 50% for daily liraglutide. But weekly exenatide came in at 47%, below daily liraglutide, and daily lixisenatide was lowest at 40% (Orsini Federici et al., Diabetes Therapy, 2018). The authors did not test these differences statistically, but the pattern is a useful warning. The device, side effects and how well the drug works can matter as much as the calendar.
For weight management specifically, a Prime Therapeutics claims analysis followed 3,364 commercially insured adults without diabetes who started a GLP-1 in 2021. After two years, 24.1% of people starting Wegovy were still taking it, versus 7.4% of those starting Saxenda. Overall one-year persistence was 28.9% (Prime Therapeutics, AMCP 2024 poster). Again, schedule is mixed up with efficacy and side effects. People who see better results are more likely to keep going.
There is no comparable long-term persistence data yet for the 2026 daily pills.
Missed doses and half-life: the hidden difference
Half-life is how long it takes the body to clear half the drug, and it shapes daily life on each schedule more than most people expect.
Weekly drugs forgive late doses
With weekly drugs, a late dose is usually manageable. The Zepbound label says to take a missed dose as soon as possible within 4 days (96 hours), and lets you change your dosing day as long as doses are at least 3 days apart (Zepbound label). Wegovy's label says to take a missed injection if the next one is more than 2 days away, and skip it if not (Wegovy label).
The trade-off is that a long half-life works in both directions. The Wegovy label notes that semaglutide stays in circulation for about 5 to 7 weeks after the last injection. If you stop because of side effects, they may take a while to fade.
Daily drugs leave faster
Liraglutide's half-life is about 13 hours. Saxenda's label says that if more than 3 days pass without a dose, you restart at the 0.6 mg starting dose and titrate up again (Saxenda label). A long weekend off can mean starting over.
Foundayo sits in between with a 29- to 49-hour half-life. Its label says to take a missed dose as soon as possible without doubling up, and to restart titration at a lower dose after 7 or more consecutive missed doses (Foundayo label).
The daily routine: not all daily drugs are equal
"Daily" can mean very different routines:
- Wegovy pill: Swallow it with a sip of water (no more than 4 ounces) and wait at least 30 minutes before eating, drinking or taking other oral medicines (NovoMedLink). That fits people who already have a quiet first-thing-in-the-morning routine.
- Foundayo: Once daily, with or without food (Foundayo label). This is the most flexible daily option.
- Saxenda: A daily injection, so 365 injections a year instead of 52.
Who each schedule tends to suit
Weekly may fit better if you...
- Forget daily medications or have an irregular schedule, such as shift work or frequent travel.
- Are comfortable with a once-a-week injection.
- Want the option with the largest trial-proven weight loss. Talk with your prescriber about whether that is necessary for your goals.
- Prefer a dose window you can shift by a few days without restarting.
Daily may fit better if you...
- Strongly prefer not to inject at all. The daily pills are the main non-injectable choices.
- Already take a daily medication and can attach a GLP-1 dose to that habit.
- Value a drug that clears within days rather than weeks if side effects become a problem.
- Are price-sensitive. As of October 2026, Novo lists the Wegovy pill at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 and 25 mg (NovoCare). Lilly lists Foundayo from $149 for the lowest dose (Lilly). Weekly Zepbound self-pay is $299 to $449 by dose for the KwikPen or vials, and the $449 KwikPen price requires a refill within 45 days (Lilly), and Wegovy pens are $349 after introductory pricing (NovoCare).
The verdict
Weekly GLP-1s are the stronger default for most people deciding today. They mean fewer doses to manage, more forgiving missed-dose windows, the best persistence data, and, with tirzepatide, the largest trial weight loss of any option in the table above. Daily dosing is no longer the weak option it was in the liraglutide era, though. The Wegovy pill and Foundayo deliver double-digit average weight loss and are the lowest-priced entry points on manufacturer self-pay lists. Choose weekly if you want convenience and maximum effect and don't mind a weekly shot. Choose daily if avoiding needles, building on an existing daily habit, or a drug that clears quickly matters more to you, and pick the daily routine (fasting or not) you can keep.
Ready to compare providers?
Check current pricing for weekly and daily GLP-1s from licensed prescribers.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Are weekly GLP-1s more effective than daily ones?
In STEP 8, weekly semaglutide produced 15.8% weight loss versus 6.4% for daily liraglutide. But that gap reflects the different drugs, not just the schedule. The daily Wegovy pill produced 13.6% in OASIS 4.
Do people stick with weekly GLP-1s longer?
Generally yes, though not always. A Prime Therapeutics analysis found 24.1% of Wegovy starters versus 7.4% of Saxenda starters still on treatment at two years. In an Italian study, weekly exenatide had lower 6-month persistence than daily liraglutide.
What happens if I miss a weekly versus a daily dose?
Zepbound's label allows a missed dose within 4 days, and Wegovy's if the next dose is more than 2 days away. Saxenda's label says to restart at 0.6 mg after more than 3 missed days, and Foundayo's says to re-titrate after 7 or more missed doses.
Which daily GLP-1 options are available for weight loss?
As of October 2026, the daily options for weight management are Saxenda (liraglutide injection), the Wegovy pill (oral semaglutide), and Foundayo (orforglipron), which can be taken with or without food.
Which schedule costs less?
Manufacturer self-pay prices for the daily pills start lower: $149 a month for the lowest Wegovy pill and Foundayo doses. Weekly Zepbound runs $299 to $449 by dose (KwikPen or vials), and Wegovy pens $349 after introductory pricing, as of October 2026.
Sources
- Eli Lilly: Zepbound prescribing information (rev. 08/2026)
- FDA: Wegovy approval package and labeling, NDA 215256/S-031 (May 2026)
- Eli Lilly: Foundayo prescribing information (rev. 07/2026)
- Novo Nordisk: Saxenda prescribing information (rev. 02/2026)
- Patient Care: Semaglutide superior to liraglutide in head-to-head study (STEP 8)
- Novo Nordisk via MarketScreener: Wegovy pill now broadly available (Jan. 2026)
- Eli Lilly: FDA approves Foundayo (orforglipron) (April 1, 2026)
- Novo Nordisk: Wegovy prescribing information, injection and tablets (rev. 06/2026)
- HCPLive: SURMOUNT-1 results
- Orsini Federici M, et al. Utilization patterns of GLP-1 receptor agonists in Italy. Diabetes Therapy, 2018
- Prime Therapeutics: GLP-1 obesity therapy adherence, persistence and switching (AMCP 2024)
- NovoMedLink: Wegovy pen and pill administration
- NovoCare: Wegovy self-pay savings offer
- Eli Lilly: Zepbound coverage and savings
- PharmExec: ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN (May 2026)
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.